Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 8:40 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1033–1056 of 5,554 matching trials from the live ClinicalTrials.gov search.

Filters: Sacramento, California Clear all

Conditions: Immediate Post-Treatment Care, Aging Mid-Face, Aging
Interventions: ariessence pure PDGF+™ is a sterile aqueous formulation containing Hyaluronic Acid and pure platelet-derived growth factor (PDGF).; Other
Lead sponsor: Lynch Regenerative Medicine; Network
Eligibility: 40 Years to 70 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Sacramento, California • Nashville, Tennessee

Conditions: Charcot-Marie-Tooth Disease
Interventions: (RS)-baclofen, naltrexone hydrochloride and D-sorbitol, Placebo; Drug
Lead sponsor: Pharnext S.C.A.; Other
Eligibility: 16 Years to 65 Years
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 20
States / cities: Los Angeles, California • Sacramento, California • New Britain, Connecticut + 16 more

Conditions: Breast Cancer, Lung Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Abraxane, Alimta; Drug
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2014
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Mycoses, Candidiasis, Invasive, Candidemia
Interventions: SCY-078, Fluconazole, Micafungin; Drug
Lead sponsor: Scynexis, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 24
States / cities: Birmingham, Alabama • Sacramento, California • Aurora, Colorado + 17 more

Conditions: Alzheimer's Disease
Interventions: MPC-7869; Drug
Lead sponsor: Myrexis Inc.; Industry
Eligibility: 55 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 84
States / cities: Alabaster, Alabama • Huntsville, Alabama • Phoenix, Arizona + 81 more

Conditions: Pancreatic Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
Interventions: Anetumab Ravtansine, Biopsy Procedure, Biospecimen Collection, Gemcitabine Hydrochloride, Ipilimumab, Nivolumab; Biological · Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 44
States / cities: Birmingham, Alabama • Duarte, California • Irvine, California + 35 more

Conditions: Brain Tumors, Central Nervous System Tumors
Interventions: etoposide, vincristine sulfate, radiation therapy; Drug · Radiation
Lead sponsor: Children's Oncology Group; Network
Eligibility: 3 Years to 21 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2007
U.S. locations: 97
States / cities: Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 73 more

Conditions: Pain
Interventions: neurostimulation system; Device
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 4,800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2035
U.S. locations: 67
States / cities: Phoenix, Arizona • Tucson, Arizona • Campbell, California + 60 more

Conditions: Acute Lymphoblastic Leukemia, Acute Undifferentiated Leukemia, Childhood T Acute Lymphoblastic Leukemia
Interventions: Asparaginase, Biospecimen Collection, Bone Marrow Biopsy, Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Dexamethasone, Echocardiography, Etoposide, Filgrastim, Laboratory Biomarker Analysis, Lestaurtinib, Leucovorin Calcium, Mercaptopurine, Methotrexate, Methylprednisolone, Multigated Acquisition Scan, Pegaspargase, Pharmacological Study, Prednisone, Therapeutic Hydrocortisone, Vincristine Sulfate; Drug · Procedure · Biological + 1 more
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 1 Year
Enrollment: 218 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2024
U.S. locations: 157
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 120 more

Conditions: Metabolic Syndrome, Insulin Resistance, Dyslipidemia
Interventions: Glucose, Fructose, High-Fructose Corn Syrup, No sugar (Aspartame); Other
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years to 40 Years
Enrollment: 214 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2014
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Lung Cancer
Interventions: carboplatin, paclitaxel, tirapazamine; Drug
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2006
U.S. locations: 93
States / cities: Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 61 more

Conditions: Limb-girdle Muscular Dystrophy
Interventions: Not listed
Lead sponsor: Sarepta Therapeutics, Inc.; Industry
Eligibility: 4 Years and older
Enrollment: 205 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2030
U.S. locations: 11
States / cities: Phoenix, Arizona • Little Rock, Arkansas • La Jolla, California + 8 more

Conditions: Pancreas Adenocarcinoma
Interventions: NovoTTF-200T, Gemcitabine, nab paclitaxel; Device · Drug
Lead sponsor: NovoCure Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 571 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 74
States / cities: Birmingham, Alabama • Mobile, Alabama • Gilbert, Arizona + 66 more

Conditions: Symptomatic Neurogenic Orthostatic Hypotension
Interventions: Droxidopa capsules, Placebo capsules; Drug
Lead sponsor: H. Lundbeck A/S; Industry
Eligibility: 18 Years and older
Enrollment: 453 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 168
States / cities: Chandler, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 103 more

Conditions: Intracerebral Hemorrhage, Atrial Fibrillation
Interventions: Apixaban, Aspirin; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 186
States / cities: Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 141 more

Conditions: HIV-1 Infection
Interventions: BMS-986001, Placebo matching with BMS-986001, Efavirenz, Lamivudine, Tenofovir; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 297 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 18
States / cities: Sacramento, California • Orlando, Florida • West Palm Beach, Florida + 15 more

Conditions: Prostate Cancer
Interventions: bicalutamide, flutamide, LHRH agonist (antagonist) therapy, Dose-Escalated Radiation Therapy; Drug · Radiation
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years and older · Male only
Enrollment: 1,538 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2025
U.S. locations: 499
States / cities: Birmingham, Alabama • Fairbanks, Alaska • Peoria, Arizona + 353 more

Conditions: Childhood Hepatocellular Carcinoma, Childhood Malignant Liver Neoplasm, Fibrolamellar Carcinoma, Hepatoblastoma, Hepatocellular Malignant Neoplasm, Not Otherwise Specified
Interventions: Biospecimen Collection, Carboplatin, Cisplatin, Doxorubicin, Etoposide, Fluorouracil, Gemcitabine, Irinotecan, Oxaliplatin, Patient Observation, Resection, Sorafenib, Vincristine Sulfate; Procedure · Drug · Other
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 30 Years
Enrollment: 537 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 180
States / cities: Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 134 more

Conditions: Cutaneous Melanoma
Interventions: Adjuvant Therapy, Comprehensive Geriatric Assessment, Computed Tomography, Positron Emission Tomography, Questionnaire Administration, Sentinel Lymph Node Biopsy, Surveillance, Ultrasound Imaging, Wide Local Excision; Procedure · Other · Behavioral
Lead sponsor: ECOG-ACRIN Cancer Research Group; Network
Eligibility: 75 Years and older
Enrollment: 428 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 181
States / cities: Birmingham, Alabama • Daphne, Alabama • Fairhope, Alabama + 142 more

Conditions: Breast Carcinoma
Interventions: Electronic Health Record Review, Health Promotion and Education, Health Telemonitoring, Patient Navigation, Survey Administration, Text Message-Based Navigation Intervention; Other · Procedure · Behavioral
Lead sponsor: ECOG-ACRIN Cancer Research Group; Network
Eligibility: 18 Years and older
Enrollment: 390 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 499
States / cities: Fairbanks, Alaska • Kingman, Arizona • Phoenix, Arizona + 338 more

Conditions: Rosacea
Interventions: Ivermectin 1% cream, Doxycycline 40 mg MR (30 mg Immediate Release & 10 mg Delayed Release beads) capsules, Oral placebo capsules; Drug · Other
Lead sponsor: Galderma R&D; Industry
Eligibility: 18 Years and older
Enrollment: 273 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 9
States / cities: Fort Smith, Arkansas • Sacramento, California • Boca Raton, Florida + 5 more

Conditions: Gastroschisis
Interventions: Bifidobacteria infantis, Placebo; Dietary Supplement · Other
Lead sponsor: University of California, Davis; Other
Eligibility: Up to 2 Weeks
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Acute Myeloid Leukemia (AML), Multiple Myeloma, Prostate Cancer, Small Cell Lung Cancer, Non-Hodgkins Lymphoma
Interventions: ABBV-075, Venetoclax; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 10
States / cities: Scottsdale, Arizona • Duarte, California • Sacramento, California + 6 more

Conditions: Operative Wound
Interventions: Everted closure, Planar closure; Other
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Sacramento, California

Search by objective public record fields.

Post-market Cosmetic Evaluation of Ariessence™ Pure PDGF+ Following Ablative Laser

Phase III Trial Assessing the Efficacy and Safety of PXT3003 in CMT1A Patients

Abraxane and Alimta in Advanced Solid Tumors

Oral Ibrexafungerp (SCY-078) vs Standard-of-Care Following IV Echinocandin in the Treatment of Invasive Candidiasis

Open-Label Treatment With MPC-7869 for Patients With Alzheimer's Who Previously Participated in an MPC-7869 Protocol

Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic Cancer

Combination Chemotherapy Plus Radiation Therapy in Treating Children With Newly Diagnosed Brain Stem Glioma

RELIEF - A Global Prospective Observational Post-Market Study to Evaluate Long-Term Effectiveness of Neurostimulation Therapy for Pain

Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

The Metabolic Effects of Consuming Sugar-Sweetened Beverages for Two Weeks

Combination Chemotherapy With or Without Tirapazamine in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer

A Study of the Natural History of Participants With LGMD2E/R4, LGMD2D/R3, LGMD2C/R5, and LGMD2A/R1 ≥ 4 Years of Age, Who Are Managed in Routine Clinical Practice

Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel (PANOVA-3)

Sustained Effect of Droxidopa in Symptomatic Neurogenic Orthostatic Hypotension

Anticoagulation in ICH Survivors for Stroke Prevention and Recovery

Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive

Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer

Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery

Comparing the Effectiveness of Less Invasive Procedures With the Current Standard of Care for the Treatment of Older Adults With Early-Stage Melanoma

Mobile Health for Adherence in Breast Cancer Patients

Oracea Soolantra Association in Participants With Severe Rosacea

Probiotics in Infants With Gastroschisis

A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer

Wound Eversion Versus Planar Closure for Face or Neck Wounds